Application of ESR1 as target spot in treatment and / or prevention of hepatic fibrosis
Through ESR1 receptor agonists, regulating estrogen receptors in liver stellate cells, inhibiting the expression of liver fibrosis-related genes, solving the problem of liver fibrosis caused by liver diseases such as MASH, providing new treatment and prevention strategies, significantly reducing the number of factors such as reducing the number of liver disease. risk of liver fibrosis.
Patent Information
- Application Number
- CN202411504274.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-25
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing technology is difficult to effectively prevent and treat liver fibrosis caused by liver diseases such as steatohepatitis (MASH) related to metabolic dysfunction. Severe liver fibrosis may lead to serious complications such as jaundice, portal hypertension, gastrointestinal bleeding and liver failure. .
By using ESR1 receptor agonists, regulating estrogen receptors in hepatic stellate cells and inhibiting the expression of liver fibrosis-related genes, providing a novel drug to treat and prevent liver fibrosis, including transplantation in mouse models Estrogen sustained release rods are placed to reduce mRNA levels of liver fibrosis-related genes.
It significantly reduces the expression of liver fibrosis-related genes and collagen fiber deposition, providing a new strategy for the clinical prevention and treatment of liver fibrosis diseases, especially for liver fibrosis caused by MASH or other liver damage.
Smart Images

Figure CN119074929A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and specifically, to the use of ESR1 as a target in the treatment and / or prevention of liver fibrosis. Background Art
[0002] Metabolic dysfunction-associated fatty liver disease (MAFLD) refers to a type of liver disease caused by known factors other than alcohol or other factors, such as viruses, drugs, etc., with one or more phenotypes of liver fatty degeneration, hepatocyte ballooning, and liver fibrosis. It is not simply fat accumulation, but will cause certain liver damage. When obvious inflammation and ballooning occur, it is called metabolic dysfunction-associated fatty liver disease (MASH). Although mild non-alcoholic steatohepatitis is considered harmless, about 1 / 4 of patients will further worsen. As people's living habits change, the incidence of non-alcoholic fatty liver is gradually increasing.
[0003] Liver fibrosis is a healing response that occurs after the liver is damaged. It is mainly manifested by the aggregation and deposition of extracellular matrix such as collagen fibers. It is a reversible process. Various diseases such as viral hepatitis caused by hepatitis B virus and hepatitis C virus infection, alcoholic liver damage, and fatty liver disease associated with metabolic dysfunction may lead to liver fibrosis. Liver fibrosis and its severity are important indicators for measuring disease progression and prognosis in patients with liver disease.
[0004] Hepatic stellate cells are an important type of non-parenchymal cells in the liver, accounting for 1 / 3 of the total number of non-parenchymal cells in the liver and 15% of the total number of cells in the liver. They are mainly located between hepatocytes and liver sinusoidal endothelial cells, that is, inside the perisinusoidal space. Hepatic stellate cells are the main source of pathological collagen after liver injury. After the liver is damaged, they are stimulated and activated to produce a large amount of collagen fibers. If liver damage continues to develop, it will eventually lead to liver fibrosis. Therefore, hepatic stellate cells have attracted much attention as an important target for liver fibrosis.
[0005] Although mild liver fibrosis does not cause serious symptoms, severe liver fibrosis and even cirrhosis can lead to complications such as jaundice, portal hypertension, gastrointestinal bleeding, and liver failure. Therefore, patients with liver fibrosis have a higher mortality rate. Summary of the invention
[0006] In order to solve the above technical problems, the present invention provides an application of an ESR1 receptor agonist in the preparation of a medicament for treating and / or preventing liver fibrosis.
[0007] In one embodiment, the liver fibrosis is liver fibrosis due to MASH or other liver diseases.
[0008] In a preferred embodiment, the other liver diseases include viral hepatitis (such as hepatitis B, hepatitis C) and autoimmune hepatitis.
[0009] The present invention proves through animal experiments that the estrogen receptor expressed by hepatic stellate cells can indeed play a regulatory role in liver diseases such as MASH, thereby inhibiting the process of liver fibrosis. In mice implanted with estrogen sustained-release rods, the mRNA levels of liver fibrosis-related genes (Col1a1, Col1a2, Col3a1 and Timp1) in the MASH model were significantly reduced compared with sham-operated mice. Estrogen supplementation can be used as an effective treatment method and has a significant therapeutic effect on liver fibrosis caused by MASH or other liver damage.
[0010] In addition, the present invention also proves through cell experiments that ESR1 can bind to a variety of motifs and different elements in hepatic stellate cells, and ESR1 can directly bind to multiple liver fibrosis-related gene sequences, playing a direct regulatory role. In vitro hepatic stellate cells activated by estrogen stimulation showed significant downregulation of liver fibrosis-related genes.
[0011] Compared with the prior art, the present invention has the following beneficial effects:
[0012] The present invention provides a new use of ESR1 as a target in the treatment or prevention of liver fibrosis, especially for liver fibrosis damage caused by MASH or other liver damage, and provides a new strategy for the prevention and treatment of liver fibrosis diseases in clinical practice. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] The accompanying drawings are used to provide a further understanding of the present invention and constitute a part of the specification. Together with the embodiments of the present invention, they are used to explain the present invention and do not constitute a limitation of the present invention. In the accompanying drawings:
[0014] Figure 1Ovariectomy exacerbates liver fibrosis in female mice in the MASH model induced by a choline- and methionine-deficient (MCD) diet. (A) Mouse treatment procedures. Wild-type female mice were subjected to ovariectomy or sham surgery and then fed a normal chow (NCD) or MCD diet. (B) HE staining of liver sections from female mice that underwent sham surgery or ovariectomy and were fed an NCD or MCD diet. (C and D) Sirius red staining of liver sections from female mice that underwent sham surgery or ovariectomy and were fed an NCD or MCD diet and quantitative analysis of the area of deposited collagen in the sections. n = 9; mean ± SEM; **p < 0.01 (independent t test). (E and F) Immunohistochemical staining and quantitative analysis of αSMA in the livers of female mice that underwent sham surgery or ovariectomy and were fed an NCD or MCD diet. n = 9; mean ± SEM; *p < 0.05 (independent t test). (G and H) Immunofluorescence staining of TIMP1 and αSMA and quantification of TIMP1 mean fluorescence intensity in the livers of female mice that underwent sham surgery or ovariectomy and were fed an NCD or MCD diet. n = 9; mean ± SEM; *p < 0.05 (independent t test). (I) Quantification of fibrosis-related mRNA expression in the livers of female mice that underwent sham surgery or ovariectomy and were fed an NCD or MCD diet. NCD group n = 5, MCD group n = 9; mean ± SEM; no significant difference; *p < 0.05 (two-way ANOVA test).
[0015] Figure 2 .ESR1, but not ESR2, is expressed in human and mouse hepatic stellate cells. (A and B) HSCs were isolated from human and mouse hepatic stellate cells by fluorescence-activated cell sorting based on retinal+ / CD45-. (C) mRNA levels of Esr1 and Esr2 in human and mouse hepatic stellate cells from male and female liver tissues. (D and E) Immunofluorescence staining of estrogen receptor and αSMA in male and female human tissues. Only Esr1 is expressed in hepatic stellate cells, and ESR1 protein colocalizes with the nucleus. (F and G) mRNA levels of Esr1 and Esr2 in male and female Lrat Cre ; RCL-ChR2(H134R) / EYFP + / - Co-immunostaining of estrogen receptor and EYFP was performed in mouse tissues. Only Esr1 was expressed in hepatic stellate cells, and ESR1 protein colocalized with the nucleus.
[0016] Figure 3 Conditional knockout of Esr1 in hepatic stellate cells exacerbates liver fibrosis in castrated female mice in the MASH model induced by MCD diet. (A and B) Lrat CreThe Lrat mouse line is an effective tool for conditional knockout of hepatic stellate cells. Cre; RCL-ChR2(H134R) / EYFP + / - In mice, Eyfp was used as a reporter gene, and 99.1% of retinal-positive hepatic stellate cells were labeled by EYFP signals. fl / fl The Esr1 mRNA level in hepatic stellate cells of mice was significantly lower than that in Lrat Cre ;Esr1 fl / fl In mouse hepatic stellate cells, the mRNA level of Esr1 is almost undetectable. (C) Cre ;Esr1 fl / fl Mice and Esr1 fl / fl HE staining of liver sections of mice fed NCD or MCD diet. (D and E) Cre ;Esr1 fl / fl Mice and Esr1 fl / fl Liver sections of mice fed an NCD or MCD diet were stained with picrosirius red and quantitatively analyzed for collagen positive staining. n = 11 or n = 13; mean ± SEM; *p < 0.05 (independent t test). (F and G) Lrat Cre ;Esr1 fl / fl Mice and Esr1 fl / fl Immunohistochemical staining and quantitative analysis of αSMA in the liver of mice fed an NCD or MCD diet. n = 11 or n = 13; mean ± SEM; **p < 0.01 (independent t test). (H and I) Cre ;Esr1 fl / fl Mice and Esr1 fl / fl Immunofluorescence staining of TIMP1 and αSMA and quantitative analysis of mean fluorescence intensity of TIMP1 in the liver of mice fed NCD or MCD diet. n = 11 or n = 13; mean ± SEM; *p < 0.05 (independent t test). (J) Cre ;Esr1 fl / fl Mice and Esr1 fl / fl Quantitative analysis of mRNA expression related to fibrosis in the liver of mice fed NCD or MCD diet. NCD group n = 5, MCD group n = 11 or n = 13; mean ± SEM; no significant difference; *p < 0.05 (two-way ANOVA test).
[0017] Figure 4.Estradiol implantation alleviates liver fibrosis in castrated male mice in the MASH model induced by an MCD diet. (A) Mouse treatment procedures. Wild-type male mice were castrated and received sham surgery or implantation of β-estradiol implants and then fed an NCD or MCD diet. (B) HE staining of liver sections of castrated male mice fed an NCD or MCD diet after sham surgery or estradiol implantation. (C and D) Sirius red staining and quantitative analysis of collagen-positive staining of liver sections of castrated male mice fed an NCD or MCD diet after sham surgery or estradiol implantation. n = 7 or n = 8; mean ± SEM; **p < 0.01 (independent t test). (E and F) Immunohistochemical staining and quantitative analysis of αSMA in livers of castrated male mice fed an NCD or MCD diet after sham surgery or estradiol implantation. n = 7 or n = 8; mean ± SEM; *p < 0.05 (independent t test). (G and H) Immunofluorescence staining of TIMP1 and αSMA and quantification of TIMP1 mean fluorescence intensity in the livers of castrated male mice fed NCD or MCD diets after sham surgery or estradiol implantation. n = 7 or n = 8; mean ± SEM; *p < 0.05 (independent t test). (I) Quantification of fibrosis-related mRNA expression in the livers of castrated male mice fed NCD or MCD diets after sham surgery or estradiol implantation. NCD group n = 5, MCD group n = 7 or n = 8; mean ± SEM; no significant difference; **p < 0.01 (two-way ANOVA test).
[0018] Figure 5 .ESR1 acts as a transcription factor to inhibit the expression of fibrosis-related genes in hepatic stellate cells. (A) ChIP-seq experimental steps. Cre ; RCL-ChR2(H134R) / EYFP + / - 5 million EYFP isolated from mice + / CD45 - Hepatic stellate cells were used for ChIP-seq analysis with anti-Esr1 antibody. (B) Lrat Cre ; RCL-ChR2(H134R) / EYFP + / -Motif analysis of ESR1 target sites in mouse hepatic stellate cells. (C) Annotation of ESR1 binding sites in hepatic stellate cells of fibrotic livers. (D) ESR1 directly targets and regulates key genes associated with liver fibrosis. The distribution of ESR1 target sites at various gene loci is shown in the figure. (E) During in vitro activation, estradiol directly downregulated the mRNA levels of fibrosis-related genes in hepatic stellate cells. Hepatic stellate cells were cultured in vitro for 6 days, and 17β-estradiol was added or not for the last 4 days, and then the cells were collected for RNA-seq analysis. The mRNA levels were normalized by setting the minimum and maximum values to 0% and 100%, respectively. (F) Schematic diagram of estrogen alleviating liver fibrosis through ESR1 in MASH. DETAILED DESCRIPTION
[0019] The preferred embodiments of the present invention are described below in conjunction with the accompanying drawings. It should be understood that the preferred embodiments described herein are only used to illustrate and explain the present invention, and are not used to limit the present invention.
[0020] In the following examples, human liver tissue was collected following a protocol approved by the Ethics Committee of Peking University People's Hospital, and informed consent was obtained from each patient. Liver tissue without detectable HBV or HCV was obtained from five patients (33 to 76 years old, male and female) during liver resection for benign or malignant liver tumors.
[0021] In the following examples, all mouse experimental operations were in accordance with the protocol approved by the Animal Experimental Ethics Committee (IACUC) of Peking University. Mice were maintained on a 12-hour light / 12-hour dark cycle (light period from 7:00 am to 7:00 pm) and had free access to food and water. Unless otherwise stated, 8-10 week old C57BL / 6 wild-type mice used in the experiments were purchased from Charles River International. Lrat Cre (C001205, Cyagen) and Esr1 fl / fl (S-CKO-02261, Cyagen) mice were mated to generate Lrat Cre ;Esr1 fl / fl Mouse. Ai32(RCL-ChR2(H134R) / EYFP) + / + Mice (JAX:012569, RRID:IMSR_JAX:012569) were purchased from Jackson Laboratory.
[0022] In the following examples, statistical methods used ImageJ 1.53K to measure the percentage of Sirius red positive area and the average optical density of TIMP1. Immunohistochemical positive staining of α-SMA was measured by the H-DAB model of ImageJ. Two-sided unpaired t-test or ANOVA test was performed by GraphPad Prism 9.5.0. Data points represent biological replicates.
[0023] Example 1 Study on the mechanism of liver fibrosis and screening of therapeutic targets
[0024] 1. Ovariectomy promotes liver fibrosis in the mouse MASH model
[0025] The ovaries of female mice were removed at 6 weeks of age to simulate the menopausal state in human clinics, and the mice were fed a choline and methionine deficient diet at 8 weeks of age to induce the mouse steatohepatitis-associated steatohepatitis (MASH) model ( Figure 1 A) From Figure 1 BI shows that compared with the control surgery group mice, the deposition of collagen fibers and liver fibrosis markers such as αSMA in the liver of ovariectomized mice after MASH modeling increased significantly, and the level of TIMP1 protein in the liver also increased significantly. TIMP1, as a metalloproteinase (MMP) inhibitor protein, can organize the degradation of collagen fibers, further promoting collagen deposition and liver fibrosis. At the same time, fluorescence quantitative PCR also showed that in female mice with ovariectomized liver fibrosis, the mRNA levels of liver fibrosis-related genes (Col1a1, Col1a2, Col3a1 and Timp1) in the MASH model were significantly higher than those in mice without ovariectomy, indicating that severe liver fibrosis is more likely to occur in postmenopausal female MASH patients.
[0026] 2. Human and mouse hepatic stellate cells express ESR1 but not ESR2
[0027] Estrogen receptors (ESRs) include ESR1 and ESR2. To identify the type of estrogen receptors expressed in hepatic stellate cells, we sorted human and mouse hepatic stellate cells using hepatic stellate cell-specific retinal fluorescence signals and used CD45 - Myeloid cell contamination was excluded. Transcriptomic sequencing was performed on these cells. We found that only Esr1 mRNA was present in these cells. At the same time, in human and mouse liver samples, we found that ESR1 protein was present in hepatic stellate cells and localized to its nucleus, while ESR2 was not present in hepatic stellate cells ( Figure 2This suggests that the ESR1 receptor in hepatic stellate cells may play an important role in the clinical phenomenon that the liver fibrosis phenotype is prone to worsening in postmenopausal women, thus predicting that it is an important target for the treatment of liver fibrosis.
[0028] Example 2 Experimental verification of ESR1 as a therapeutic target for inhibiting liver fibrosis
[0029] We used the Cre-Lox recombination system to utilize the hepatic stellate cell-specific Lrat Cre Mouse strains and Esr1 fl / fl We hybridized the mouse strains and specifically knocked out the ESR1 receptor gene in the hepatic stellate cells of the mice. We then used MASH modeling to induce liver fibrosis in the mice. We found that after knocking out the ESR1 receptor in the hepatic stellate cells, the phenotype of the mice was similar to that after ovariectomy. The amount of collagen fiber deposition and the expression of αSMA were significantly increased, and the protein level of TIMP1 in the liver was also significantly increased. At the same time, quantitative fluorescence PCR (also showed that in Lrat Cre ;Esr1 fl / fl In the liver of female mice, the mRNA levels of liver fibrosis-related genes (Col1a1, Col1a2, Col3a1, and Timp1) were significantly higher in the MASH model than in the Esr1 fl / fl Mice had significantly increased ( Figure 3 This indicates that the estrogen receptor expressed by hepatic stellate cells can indeed play a regulatory role in liver diseases such as MASH, thereby inhibiting the progression of liver fibrosis.
[0030] To further verify whether ESR1 can be used as a therapeutic target to treat liver fibrosis in clinic, we removed the testicles of male mice at 4 weeks of age to reduce the level of sex hormones in their bodies. At 7 weeks, they were divided into two groups and implanted with estrogen sustained-release rods (the main active ingredient is estradiol) or underwent sham surgery. At 8 weeks of age, the MASH model and liver fibrosis were induced by MCD diet. The results showed ( Figure 4 AI), compared with the sham operation group, the deposition of collagen fibers and the expression of αSMA in mice implanted with estrogen sustained-release rods were significantly decreased, and the protein level of TIMP1 in the liver was also significantly decreased. At the same time, fluorescence quantitative PCR also showed that in mice implanted with estrogen sustained-release rods, the mRNA levels of liver fibrosis-related genes (Col1a1, Col1a2, Col3a1 and Timp1) in the MASH model were significantly decreased compared with sham operation mice. Estrogen supplementation can be used as an effective treatment for liver fibrosis caused by MASH or other liver damage.
[0031] Example 3 Study on the mechanism of ESR1 receptor inhibiting liver fibrosis
[0032] ChIP-seq was used to analyze the binding sites of ESR1 in the hepatic stellate cell genome, and it was found that ESR1 can bind to a variety of motifs and different elements in hepatic stellate cells. At the same time, ESR1 can directly bind to multiple liver fibrosis-related gene sequences and play a direct regulatory role ( Figure 5 AD). In vitro, hepatic stellate cells activated by estrogen stimulation showed significant downregulation of liver fibrosis-related genes ( Figure 5 E), which further proves that estrogen directly binds to the estrogen receptor in hepatic stellate cells ( Figure 5 F), directly involved in the downregulation of liver fibrosis-related genes, thereby inhibiting the progression of liver fibrosis.
[0033] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. Use of ESR1 receptor agonists in the preparation of drugs for treating and / or preventing liver fibrosis.
2. The use according to claim 1, characterized in that The liver fibrosis is liver fibrosis caused by MASH or other liver injuries.
3. The use according to claim 2, characterized in that The other liver injuries include diseases such as viral hepatitis (such as hepatitis B, hepatitis C) and autoimmune hepatitis.
Citation Information
Patent Citations
Application of estrogen
CN103055314A
Treatment of Fibrotic Conditions
US20200108069A1
